Drug-Coated Balloons Global Market Report 2024

The drug-coated balloons market has grown rapidly in recent years. It will grow from $0.95 billion in 2023 to $1.1 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%.The growth observed in the historical period can be ascribed to a heightened burden of cardiovascular diseases, a surge in the demand for minimally invasive procedures, the prevalence of peripheral artery disease (PAD), decreasing restenosis rates, and advancements in interventional cardiology.

The drug-coated balloons market is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 15.0%. The anticipated growth in the forecast period can be credited to the rising aging population, the broadening of indications and applications, a focus on outpatient and ambulatory care, integration with innovations in drug delivery, and global health initiatives. Major trends expected in the forecast period encompass regulatory approvals for new formulations, a focus on minimizing side effects, the emergence of bioresorbable coatings, market expansion in emerging economies, and patient-centric approaches.

The anticipated rise in the prevalence of coronary artery disease is poised to drive the growth of the drug-coated balloons market. Coronary artery disease (CAD) is characterized by the narrowing or obstruction of the coronary arteries, which supply blood to the heart muscle, potentially leading to heart attacks. Drug-coated balloons are medical devices employed in the treatment of coronary artery disease, releasing medication into the artery during the procedure to mitigate the risk of restenosis, the re-narrowing of the artery post-angioplasty. For instance, a report by the Centers for Disease Control and Prevention in May 2023 revealed an increase in coronary heart disease deaths to 375,476 in the United States in 2021, with about 1 in 20 adults aged 20 and older diagnosed with coronary heart disease. Consequently, the upsurge in the prevalence of coronary artery disease is expected to bolster the drug-coated balloon market.

The increasing number of ambulatory surgery centers is anticipated to propel the growth of the drug-coated balloon market. Ambulatory Surgical Centers (ASCs) are medical facilities dedicated to conducting surgical procedures that do not necessitate an overnight hospital stay. Drug-coated balloons play a crucial role in ASCs by offering shorter procedure times compared to standard balloons, resulting in improved patient throughput and reduced operational costs. For instance, VMG Health reported in September 2023 that the total number of Medicare-certified ambulatory surgery centers increased by 2.9% from 1752 in 2021 to 1804 in 2022. Hence, the growing prevalence of ambulatory surgery centers is a driving force behind the drug-coated balloon market's expansion.

Product innovations represent a prominent trend gaining momentum in the drug-coated balloons market. Leading companies in the market are actively engaged in the development of new and innovative technological solutions to fortify their market position. An illustration of this trend is evident in Medtronic plc's introduction of the Prevail drug-coated balloon (DCB) Catheter in July 2021. This state-of-the-art tool is employed in percutaneous coronary intervention (PCI) procedures to address coronary artery disease (CAD) by delivering targeted therapy to blocked or constricted coronary arteries. Utilizing paclitaxel, a rapidly absorbable medication, this DCB enables effective treatment of various lesions, including in-stent restenosis (ISR), small vascular disease, and de novo lesions.

Major players in the drug-coated balloons market are strategically embracing collaboration and partnerships to enhance service delivery. A strategic partnership involves a structured affiliation between two or more commercial enterprises, typically established through business agreements or contracts. For example, in February 2021, Cardiovascular Systems Inc., a US-based provider of cardiovascular medical devices, entered into a partnership with Chansu Vascular Technologies LLC, a US-based manufacturer of peripheral and coronary DCBs. The collaboration aims to develop novel coronary and peripheral everolimus drug-coated balloons (DCBs) by leveraging CVT's proprietary drug-coating technology and CSI's expertise in balloon catheter design and manufacturing. This partnership aims to create next-generation DCBs that offer enhanced safety and efficacy for patients with peripheral artery disease (PAD) and coronary artery disease (CAD).

In November 2022, Cordis, a US-based manufacturer of interventional cardiovascular technologies, completed the acquisition of Med Alliance SA for $1.1 billion. Through this acquisition, Cordis aims to globally provide the drug-eluting balloon SELUTION SLRTM (Sustained Limus Release) to two million patients by 2027. Med Alliance SA, based in Switzerland, is a developer of the sirolimus micro-reservoir drug-coated balloon.

Major companies operating in the drug-coated balloons market report are Acotec Scientific AG, AR Baltic Medical AB, B. Braun Melsungen AG, Becton Dickinson and Company, Biosensors International Group Ltd., Medtronic Inc., Koninklijke Philips N.V, Boston Scientific Corporation, Opto Circuits, Acrostak Corp., BioMed, Concept Medical, Cardionovum GmbH, Endocor GmbH, Hexacath Sverige, iVascular SLU, Minvasys SAS, MedAlliance, QT Vascular Ltd., RD Global-Invamed, Terumo Corporation, Biotronik, Cook Medical, Cordis Corporation, Abbott Laboratories, Surmodics Inc., Hexacath SAS, MicroPort, SurModics Inc., Orchestra BioMed.

North America was the largest region in the global drug-coated balloons market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the drug-coated balloons market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug-coated balloons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of products encompassed within drug-coated balloons include those tailored for peripheral artery disease, coronary artery disease, and other indications. Drug-coated balloons (DCBs) for peripheral artery disease are a specific type of medical device utilized in addressing peripheral artery disease (PAD). PAD is characterized by the narrowing or blockage of blood vessels outside the heart or in the lower extremities. Various drug types, such as paclitaxel and sirolimus, are employed, and the end-users encompass hospitals, cardiac catheterization labs, and ambulatory surgical centers.

The drug-coated balloons market research report provides drug-coated balloons market statistics, including drug-coated balloons industry global market size, regional shares, competitors with a drug-coated balloons market share, detailed drug-coated balloons market segments, market trends and opportunities, and any further data you may need to thrive in the drug-coated balloons industry. This drug-coated balloons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug-coated balloons market consists of sales of everolimus and zotarolimus drug-coated balloons. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.